Searchable abstracts of presentations at key conferences in endocrinology

ea0029p1741 | Thyroid (non-cancer) | ICEECE2012

Increase of Serum Adiponectin And Stable Concentrations of Matrix Metalloproteinases Confirm Safety of Radioiodine Treatment of Thyrotoxicosis

Lewinski A. , Brona A. , Lewandowski K. , Bienkiewicz M. , Milewicz A.

Background: Matrix metalloproteinases (MMPs), together with their tissue inhibitors (TIMPs), remodel extracellular matrix under physiological and pathological conditions and are implicated in pathogenesis of cardiovascular diseases, cancer and in chronic inflammation. We have endeavoured to assess whether concentrations of MMPs, TIMPs, proinflammtory thrombospondin and anti-inflammatory adiponectin are altered by administration of radioiodine during treatment of thyrotoxicosis...

ea0029p179 | Bone & Osteoporosis | ICEECE2012

Successful treatment of thyrotoxicosis is accompanied by a decrease in serum sclerostin levels

Skowronska-Jozwiak E. , Krawczyk-Rusiecka K. , Lewandowski K. , Adamczewski Z. , Bienkiewicz M. , Lewinski A.

Sclerostin, a product of a SOST gene, is a protein expressed by osteocytes that inhibits osteoblastic bone formation. Several hormones including PTH and glucocorticosteroids and have been suggested as possible regulators of sclerostin production. The influence of thyroid hormones on sclerostin synthesis has not been investigated so far. The aim of the study was to evaluate sclerostin concentrations in patients before and after treatment of thyrotoxicosis.<p class="abstext"...